Ibyerekeye-kanseri / kuvura / ivuriro-ibigeragezo / indwara / kanseri-anal / kuvura

Kuvura Ibizamini bya Clinical Anal Kanseri

Igeragezwa rya Clinical ni ubushakashatsi bwubushakashatsi burimo abantu. Ibizamini byamavuriro kururu rutonde ni kuvura kanseri. Ibigeragezo byose kurutonde bishyigikiwe na NCI.

Amakuru yibanze ya NCI kubyerekeye ibizamini byamavuriro asobanura ubwoko nicyiciro cyibigeragezo nuburyo bikorwa. Igeragezwa rya Clinical rireba uburyo bushya bwo kwirinda, gutahura, cyangwa kuvura indwara. Urashobora gushaka gutekereza kubijyanye no kwitabira ikizamini cyamavuriro. Vugana na muganga wawe kugirango agufashe guhitamo niba umwe akubereye.

Ikigeragezo 1-23 kuri 23

Nivolumab nyuma yubuvuzi bukomatanyije bwo kuvura abarwayi bafite ibyago byinshi Icyiciro cya II-IIIB Kanseri ya Anal

Igeragezwa ryicyiciro cya kabiri cyamavuriro yiga uburyo nivolumab nyuma yo kuvura uburyo bwo kuvura ikora muburyo bwo kuvura abarwayi bafite kanseri yo mu cyiciro cya II-IIIB. Immunotherapy hamwe na antibodiyite za monoclonal, nka nivolumab, irashobora gufasha umubiri wumubiri gutera kanseri, kandi irashobora kubangamira ubushobozi bwingirabuzimafatizo zikura no gukwirakwira.

Aho uherereye: 744

Nivolumab hamwe na Ipilimumab cyangwa idafite mu kuvura abarwayi bafite kanseri yo mu bwoko bwa Anast Canal

Iki cyiciro cya II cyigeragezo cyiga uburyo nivolumab ifite cyangwa idafite ipilimumab ikora mukuvura abarwayi bafite kanseri yo mu kanwa itigeze yitabira ubuvuzi bwabanje (retractory) kandi ikwirakwira ahandi mu mubiri (metastatike). Immunotherapy hamwe na antibodiyite za monoclonal, nka nivolumab na ipilimumab, irashobora gufasha sisitemu yumubiri yumubiri gutera kanseri, kandi irashobora kubangamira ubushobozi bwingirabuzimafatizo yibibyimba gukura no gukwirakwira.

Aho uherereye: 42

Nivolumab na Ipilimumab mu kuvura abarwayi banduye virusi itera sida Yongeye kwisubiraho cyangwa yangiritse ya Classic Hodgkin Lymphoma cyangwa Ibibyimba bikomeye Bipima cyangwa bidashobora gukurwaho no kubagwa

Iki cyiciro cya I cyigeragezo cyiga ku ngaruka n’igipimo cyiza cya nivolumab iyo gitanzwe na ipilimumab mu kuvura abarwayi bafite virusi itera immunodeficiency (virusi itera SIDA) ifitanye isano na lymphoma ya kera ya Hodgkin yagarutse nyuma yigihe runaka cyo gutera imbere cyangwa kutitabira kwivuza, cyangwa ibibyimba bikomeye ibyo yakwirakwiriye ahandi mu mubiri cyangwa ntishobora gukurwaho no kubagwa. Immunotherapy hamwe na antibodiyite za monoclonal, nka ipilimumab na nivolumab, birashobora gufasha umubiri wumubiri kwibasira kanseri, kandi bishobora kubangamira ubushobozi bwingirabuzimafatizo yibibyimba gukura no gukwirakwira. Ipilimumab ni antibody ikora kurwanya molekile yitwa cytotoxic T-lymphocyte antigen 4 (CTLA-4). CTLA-4 igenzura igice cya sisitemu yumubiri wawe uyifunga. Nivolumab ni ubwoko bwa antibody yihariye ku rupfu rwabantu rwateguwe 1 (PD-1), poroteyine ishinzwe gusenya ingirabuzimafatizo. Guha ipilimumab hamwe na nivolumab birashobora gukora neza mukuvura abarwayi ba virusi itera sida ya Hodgkin ya lymphoma cyangwa ibibyimba bikomeye ugereranije na ipilimumab na nivolumab yonyine.

Aho uherereye: ahantu 28

Inyigo ya XmAb®20717 mubintu hamwe na Byatoranijwe Bikomeye Byibibyimba

Iki nicyiciro cya 1, igipimo cyinshi, ubushakashatsi bwiyongera bwa dose escalation kugirango busobanure MTD / RD nuburyo bwa XmAb20717, gusobanura umutekano no kwihanganirana, gusuzuma PK na immunogenicite, no gusuzuma mbere na mbere ibikorwa byo kurwanya ibibyimba bya XmAb20717 mubisomo byatoranijwe ibibyimba bikomeye.

Aho uherereye: ahantu 15

Iperereza ryakozwe na Immuno-therapy Inyigo yo gukora iperereza ku mutekano n’ingirakamaro bya Nivolumab, hamwe nubuvuzi bwa Nivolumab mu kuvura indwara ziterwa na virusi.

Intego yubu bushakashatsi yo gukora iperereza ku mutekano n’ingirakamaro bya nivolumab, hamwe n’ubuvuzi bwa nivolumab, kuvura abarwayi bafite ibibyimba biterwa na virusi. Virusi zimwe zizwiho kugira uruhare mukubyimba no gukura. Ubu bushakashatsi buzasesengura ingaruka z’imiti y’ubushakashatsi, ku barwayi bafite ibibyimba bikurikira: - Kanseri yo mu muyoboro w’amaraso-Ntibikiri kwandikisha ubu bwoko bw’ibibyimba - Kanseri y'inkondo y'umura - Epstein Barr Virus (EBV) kanseri nziza yo mu gifu-Ntibikiyandikisha ibi ubwoko bw'ikibyimba - Kanseri y'akagari ka Merkel - Kanseri y'imboro-Ntibikiri kwiyandikisha muri ubu bwoko bw'ikibyimba - Kanseri yo mu nda ibyara na vulvar-Ntibikiri kwiyandikisha muri ubu bwoko bw'ikibyimba - Kanseri ya Nasopharyngeal - Ntukiyandikisha ubu bwoko bw'ikibyimba - Kanseri yo mu mutwe no mu ijosi - Ntabwo ukiyandikisha ubu bwoko bw'ikibyimba

Aho uherereye: ahantu 10

Kwiga Pembrolizumab (MK-3475) mubitabiriye amahugurwa afite ibibyimba bikomeye (MK-3475-158 / KEYNOTE-158)

Muri ubu bushakashatsi, abitabiriye amahugurwa bafite ubwoko bwinshi bwibibyimba byateye imbere (bidashoboka kandi / cyangwa metastatike) byateye imbere kurwego rwo kuvura ubuvuzi bazavurwa na pembrolizumab.

Aho uherereye: ahantu 8

Indwara ya Dose-Igipimo cya Brachytherapy na Chimiotherapie mukuvura abarwayi bafite kanseri igaruka cyangwa isigaye cyangwa kanseri isigaye cyangwa kanseri ya Anal ikorerwa mubuyobozi budakora.

Iki cyiciro cya I ikigeragezo cyiga ku ngaruka mbi hamwe nigipimo cyiza cya brachytherapy ikabije-mugihe itanzwe hamwe na chimiotherapie mukuvura abarwayi ba kanseri yu mura cyangwa anal yagarutse cyangwa yarushijeho kuba mubi kandi idashobora kuvurwa no kubagwa. Brachytherapy, izwi kandi nk'imiti ivura imirasire y'imbere, ikoresha ibikoresho bya radiyoyoka bishyirwa mu kibyimba cyangwa hafi yacyo kugira ngo byice selile. Brachytherapy ikabije cyane (HDR) ikoresha ibikoresho bya radio kugirango itange imishwarara myinshi mugihe gito mugihe kibyimba. Irashobora kandi kohereza imirasire mike mubice byegeranye kandi bishobora kugabanya ingaruka zingaruka. Ibiyobyabwenge bikoreshwa muri chimiotherapie, nka capecitabine na fluorouracil, bikora muburyo butandukanye bwo guhagarika imikurire ya selile yibibyimba, haba mukwica selile, kubabuza gutandukana, cyangwa kubabuza gukwirakwira.

Aho uherereye: ahantu 6

Pembrolizumab mu kuvura abarwayi bafite Kanseri ya Anastastique cyangwa Iterambere ryaho idashobora gukurwaho no kubagwa

Iki cyiciro cya II cyigeragezo cyiga uburyo pembrolizumab ikora neza mukuvura abarwayi ba kanseri yanduye yakwirakwiriye ahandi mu mubiri cyangwa ikaba yarakwirakwiriye kuva aho yakuriye ikagera kumubiri cyangwa hafi ya lymph node kandi ntishobora gukurwaho no kubagwa. Immunotherapy hamwe na antibodiyite za monoclonal, nka pembrolizumab, irashobora gufasha umubiri wumubiri gutera kanseri, kandi irashobora kubangamira ubushobozi bwingirabuzimafatizo zikura no gukwirakwira.

Aho uherereye: ahantu 5

Kubaga mu kuvura abarwayi bafite icyiciro cya mbere cya Anal Canal cyangwa Kanseri ya Periyale na virusi itera sida

Iki cyiciro cya II cyigeragezo cyiga kubaga kuvura abarwayi bafite kanseri ya anal cyangwa kanseri ya perianal ntoya kandi itakwirakwiriye cyane mubice ndetse na virusi ya immunodeficiency ya virusi itera SIDA. Kubaga kwaho birashobora kuba uburyo bwiza bwo kuvura hamwe ningaruka nkeya kuruta kubagwa gukomeye cyangwa imirasire hamwe na chimiotherapie.

Aho uherereye: ahantu 5

Ikigeragezo cyo gushakisha no gukora iperereza ku mutekano wuzuye wibintu bishya (BI 754091) kubarwayi bafite ibibyimba bikomeye

Intego nyamukuru yikigero cya dose-escalation yikigeragezo ni ukumenya umutekano no kwihanganira, no kumenya igipimo ntarengwa cyo kwihanganira hamwe na / cyangwa icyiciro cya 2 cyateganijwe (RP2D) cya BI 754091 hashingiwe kubarwayi bafite imiti igabanya ubukana. uburozi (DLTs) mu barwayi bafite indwara mbi zateye imbere. Umutekano no kwihanganira bizasuzumwa no gukurikirana ibibaho (AEs), AEs zikomeye (SAE), hamwe na laboratoire idasanzwe, kimwe nimpinduka zerekana ibimenyetso byingenzi. Intego za kabiri ni ukumenya umwirondoro wa PK wa BI 754091 nyuma yikigereranyo kimwe na byinshi bya BI 754091, hamwe nisuzuma ryibanze ryibikorwa bya antitumour. Mugice cyo kwagura igice cyikigeragezo, intego nyamukuru nugusuzuma neza umutekano, efficacy, umwirondoro wa PK,

Aho uherereye: ahantu 3

Stereotactique Radiosurgie yo kuvura abarwayi bafite indwara ya Oligometastique

Iki cyiciro cya II cyigeragezwa cyiga uburyo radiosurgie ya stereotactique ikora neza mukuvura abarwayi ba kanseri yakwirakwiriye ahantu 5 cyangwa hato mumubiri kandi harimo ingingo 3 cyangwa nkeya (indwara ya oligometastique). Stereotactique radiosurgie, izwi kandi kwizina rya stereotactique yumubiri wumuriro, nubuvuzi bwihariye butanga imishwarara itanga urugero rumwe, rwinshi rwimirasire yibibyimba kandi bishobora kwica selile nyinshi yibibyimba kandi bigatera kwangirika kwimyanya isanzwe.

Aho uherereye: ahantu 3

Ubushakashatsi bwa INCMGA00012 muri Carcinoma ya squamous yo mu muyoboro wa Anal Ukurikira Chimoterapi ishingiye kuri platine (POD1UM-202)

Intego yubu bushakashatsi ni ugusuzuma imikorere ya INCMGA00012 mubitabiriye hamwe na kanseri yateye imbere cyangwa metastatike ya kanseri yo mu muyoboro wa anal (SCAC) yateye imbere nyuma ya chimiotherapie ishingiye kuri platine.

Aho uherereye: ahantu 4

Artesunate mukuvura abarwayi bafite Anal-Grade Anal Intraepithelial Neoplasia

Iki cyiciro cya I ikigeragezo cyiga ku ngaruka n'ingaruka nziza ya artesunate mu kuvura abarwayi bafite anal intraepithelial neoplasia yo mu rwego rwo hejuru. Anop intraepithelial neoplasia ni selile preancerous selile ishobora cyangwa idashobora guhinduka kanseri mugihe kizaza. Inyinshi mu mpinduka zitera kanseri ziterwa na papillomavirus ya muntu (HPV). Artesunate irashobora kwica selile zanduye HPV.

Aho uherereye: ahantu 2

Ubushakashatsi bwa LY3434172, PD-1 na PD-L1 Antibody Bispecific Antibody, muri Kanseri Yambere

Intego nyamukuru yubu bushakashatsi ni ugusuzuma umutekano n’ubworoherane bw’imiti y’ubushakashatsi LY3434172, antibody ya PD-1 / PD-L1, abitabiriye bafite ibibyimba bikomeye.

Aho uherereye: MD Anderson Centre ya Kanseri, Houston, Texas

SL-279252 (PD1-Fc-OX40L) mubintu bifite ibibyimba bikomeye cyangwa Lymphoma

Iki nicyiciro cya 1 cyambere mubantu, ikirango gifunguye, centre-centre, dose escalation hamwe nubushakashatsi bwagutse kugirango harebwe umutekano, kwihanganira, PK, ibikorwa byo kurwanya ibibyimba n'ingaruka za farumasi ya SL-279252 mubisomo bifite ibibyimba bikomeye cyangwa lymphoma .

Aho uherereye: MD Anderson Centre ya Kanseri, Houston, Texas

REKA-IMPT hamwe na Chimiotherapie isanzwe mu kuvura abarwayi bafite icyiciro gishya cyapimwe I-III Umuyoboro wa Anal Umuyoboro wa kanseri y'utugari

Iki cyiciro cya II cyigeragezo cyiga ku ngaruka ziterwa na LET-IMPT hamwe na chimiotherapie isanzwe, nuburyo bakora neza mukuvura abarwayi bafite icyiciro gishya cya I-III anal kanal kanseri ya kanseri. LET-IMPT ni ubwoko bwimiti ivura imirasire ikoresha ingufu za proton "beamlets" kugirango "irangi" igipimo cyimirasire mumigambi kandi gishobora gufasha kwica selile yibibyimba no kugabanya ibibyimba. Gutanga LET-IMPT hamwe na chimiotherapie isanzwe birashobora gukora neza mukuvura abarwayi bafite kanseri ya anal kanseri ya kanseri.

Aho uherereye: MD Anderson Centre ya Kanseri, Houston, Texas

VGX-3100 na Electroporation mu kuvura abarwayi bafite virusi itera SIDA-Indwara yo mu rwego rwo hejuru

Iki cyiciro cya II cyiga uburyo papillomavirus yumuntu (HPV) deoxyribonucleic aside (ADN) plasmide ivura urukingo rwa VGX-3100 (VGX-3100) hamwe n amashanyarazi yo kuvura abarwayi bafite virusi itera immunodeficiency (VIH) -ibikomere byo mu rwego rwo hejuru. Inkingo zakozwe muri ADN zishobora gufasha umubiri kubaka ubudahangarwa bw'umubiri bwo kwica selile. Electroporation ifasha imyenge yo mu ngirabuzimafatizo z'umubiri wawe gufata imiti kugirango ikomeze umubiri wawe. Gutanga VGX-3100 hamwe na electroporation hamwe birashobora gukora neza mukuvura abarwayi bafite ibikomere byo murwego rwo hejuru.

Aho uherereye: ahantu 2

ADN Plasmid-encoding Interleukin-12 / HPV ADN Plasmide ivura urukingo rwa INO-3112 na Durvalumab mu kuvura abarwayi bafite kanseri yisubiramo cyangwa Metastatike ya Papillomavirus Yanduye

Iki cyiciro cya II cyigeragezo cyiga uburyo aside ya deoxyribonucleic (ADN) plasmid-encoding interleukin-12 / papillomavirus yumuntu (HPV) ADN plasmide ivura urukingo INO-3112 hamwe na durvalumab ikora mukuvura abarwayi bafite papillomavirus yabantu kanseri yagarutse cyangwa ikwirakwira mubindi imyanya mu mubiri. Inkingo zakozwe na virusi yahinduwe na gene zishobora gufasha umubiri kubaka ubudahangarwa bw'umubiri bwo kwica selile. Immunotherapy hamwe na antibodiyite za monoclonal, nka durvalumab, irashobora gufasha umubiri wumubiri kwibasira kanseri, kandi irashobora kubangamira ubushobozi bwingirabuzimafatizo yibibyimba gukura no gukwirakwira. Guha ADN plasmid-encoding interleukin-12 / HPV ADN plasmide urukingo rwo kuvura INO-3112 na durvalumab birashobora gukora neza mukuvura abarwayi barwaye kanseri ifitanye isano na papillomavirus.

Aho uherereye: MD Anderson Centre ya Kanseri, Houston, Texas

M7824 mubintu hamwe na HPV Associated Malignancies

Amavu n'amavuko: Muri Amerika, buri mwaka hari abantu barenga 30.000 barwaye kanseri ifitanye isano na papillomavirus (HPV). Zimwe muri izo kanseri akenshi zidakira kandi ntizitezimbere nubuvuzi busanzwe. Abashakashatsi bifuza kureba niba ibiyobyabwenge bishya M7824, byibasira kandi bikabuza inzira ibuza ubudahangarwa bw'umubiri kurwanya kanseri neza bishobora kugabanya ibibyimba ku bantu bafite kanseri zimwe na zimwe za HPV. Intego: Kureba niba imiti M7824 itera ibibyimba kugabanuka. Abemerewe: Abakuze bafite imyaka 18 nayirenga bafite kanseri ifitanye isano na virusi ya HPV. Igishushanyo: Abitabiriye amahugurwa bazerekanwa n'amateka y'ubuvuzi n'ikizamini cy'umubiri. Bazasubiramo ibimenyetso byabo nuburyo bakora ibikorwa bisanzwe. Bazagira scan yumubiri. Bazatanga amaraso hamwe ninkari. Bazagira icyitegererezo cyibibyimba byabo byafashwe niba imwe itabonetse. Abitabiriye amahugurwa bazagira electrocardiogram yo gusuzuma umutima wabo. Noneho bazabona ibiyobyabwenge byo kwiga babinyujije mu muyoboro muto. Abitabiriye amahugurwa bazabona ibiyobyabwenge buri byumweru 2 inshuro 26 (umwaka 1). Iri ni isomo 1. Nyuma yamasomo, abitabiriye amahugurwa bazakurikiranwa ariko ntibazafata ibiyobyabwenge byo kwiga. Niba ubuzima bwabo bumeze nabi, bazatangira andi masomo nibiyobyabwenge. Iyi nzira irashobora gusubirwamo inshuro nyinshi bikenewe. Umuti uzahagarara niba abahugurwa bafite ingaruka mbi cyangwa ibiyobyabwenge bihagarika gukora. Mu bushakashatsi bwose, abitabiriye amahugurwa bazasubiramo bimwe cyangwa ibizamini byo gusuzuma. Abitabiriye amahugurwa nibareka gufata ibiyobyabwenge, bazasurwa hanyuma basubiremo ibizamini bimwe na bimwe. Bazabona buri gihe gukurikirana telefone. ... Noneho bazabona ibiyobyabwenge byo kwiga babinyujije mu muyoboro muto. Abitabiriye amahugurwa bazabona ibiyobyabwenge buri byumweru 2 inshuro 26 (umwaka 1). Iri ni isomo 1. Nyuma yamasomo, abitabiriye amahugurwa bazakurikiranwa ariko ntibazafata ibiyobyabwenge byo kwiga. Niba ubuzima bwabo bumeze nabi, bazatangira andi masomo nibiyobyabwenge. Iyi nzira irashobora gusubirwamo inshuro nyinshi bikenewe. Umuti uzahagarara niba abahugurwa bafite ingaruka mbi cyangwa ibiyobyabwenge bihagarika gukora. Mu bushakashatsi bwose, abitabiriye amahugurwa bazasubiramo bimwe cyangwa ibizamini byo gusuzuma. Abitabiriye amahugurwa nibareka gufata ibiyobyabwenge, bazasurwa hanyuma basubiremo ibizamini bimwe na bimwe. Bazabona buri gihe gukurikirana telefone. ... Noneho bazabona ibiyobyabwenge byo kwiga babinyujije mu muyoboro muto. Abitabiriye amahugurwa bazabona ibiyobyabwenge buri byumweru 2 inshuro 26 (umwaka 1). Iri ni isomo 1. Nyuma yamasomo, abitabiriye amahugurwa bazakurikiranwa ariko ntibazafata ibiyobyabwenge byo kwiga. Niba ubuzima bwabo bumeze nabi, bazatangira irindi somo nibiyobyabwenge. Iyi nzira irashobora gusubirwamo inshuro nyinshi bikenewe. Umuti uzahagarara niba abahugurwa bafite ingaruka mbi cyangwa ibiyobyabwenge bihagarika gukora. Mu bushakashatsi bwose, abitabiriye amahugurwa bazasubiramo bimwe cyangwa ibizamini byo gusuzuma. Abitabiriye amahugurwa nibareka gufata ibiyobyabwenge, bazasurwa hanyuma basubiremo ibizamini bimwe na bimwe. Bazabona buri gihe gukurikirana telefone. ... abitabiriye amahugurwa bazakurikiranwa ariko ntibazafata ibiyobyabwenge byo kwiga. Niba ubuzima bwabo bumeze nabi, bazatangira irindi somo nibiyobyabwenge. Iyi nzira irashobora gusubirwamo inshuro nyinshi bikenewe. Umuti uzahagarara niba abahugurwa bafite ingaruka mbi cyangwa ibiyobyabwenge bihagarika gukora. Mu bushakashatsi bwose, abitabiriye amahugurwa bazasubiramo bimwe cyangwa ibizamini byo gusuzuma. Abitabiriye amahugurwa nibareka gufata ibiyobyabwenge, bazasurwa hanyuma basubiremo ibizamini bimwe na bimwe. Bazabona buri gihe gukurikirana telefone. ... abitabiriye amahugurwa bazakurikiranwa ariko ntibazafata ibiyobyabwenge byo kwiga. Niba ubuzima bwabo bumeze nabi, bazatangira andi masomo nibiyobyabwenge. Iyi nzira irashobora gusubirwamo inshuro nyinshi bikenewe. Umuti uzahagarara niba abahugurwa bafite ingaruka mbi cyangwa ibiyobyabwenge bihagarika gukora. Mu bushakashatsi bwose, abitabiriye amahugurwa bazasubiramo bimwe cyangwa ibizamini byo gusuzuma. Abitabiriye amahugurwa nibareka gufata ibiyobyabwenge, bazasurwa hanyuma basubiremo ibizamini bimwe na bimwe. Bazabona buri gihe gukurikirana telefone. ... Abitabiriye amahugurwa nibareka gufata ibiyobyabwenge, bazasurwa hanyuma basubiremo ibizamini bimwe na bimwe. Bazabona buri gihe gukurikirana telefone. ... Abitabiriye amahugurwa nibareka gufata ibiyobyabwenge, bazasurwa hanyuma basubiremo ibizamini bimwe na bimwe. Bazabona buri gihe gukurikirana telefone. ...

Aho biherereye: Ikigo cyigihugu cyita ku buzima Clinical Centre, Bethesda, Maryland

MnSOD Yigana BMX-001 mukuvura abarwayi bafite kanseri ya Anal barimo kuvura imishwarara hamwe na chimiotherapie

Iki cyiciro cya I ikigeragezo cyiga igipimo cyiza cya MnSOD yigana BMX-001 kugirango igabanye ingaruka mbi kubarwayi barwaye kanseri yo mu nda barimo kuvura imirasire na chimiotherapie. Imiti ya chimoprotective, nka BMX-001, irashobora kurinda selile zisanzwe ingaruka ziterwa na chimiotherapie mugihe byongera ubwicanyi bwibibyimba.

Aho uherereye: Ikigo cy’ubuvuzi cya kaminuza ya Nebraska, Omaha, Nebraska

Atezolizumab na Bevacizumab mu kuvura abarwayi bafite ibibyimba bidasanzwe

Iki cyiciro cya kabiri cyikigereranyo cyiga uburyo atezolizumab na bevacizumab bikora neza mukuvura abarwayi bafite ibibyimba bidasanzwe. Immunotherapy hamwe na antibodiyite za monoclonal, nka atezolizumab na bevacizumab, birashobora gufasha sisitemu yumubiri yumubiri gutera kanseri, kandi bishobora kubangamira ubushobozi bwingirabuzimafatizo yibibyimba gukura no gukwirakwira.

Aho uherereye: MD Anderson Centre ya Kanseri, Houston, Texas

Ubuvuzi bw'inkingo hamwe na Cyclophosphamide mu kuvura abarwayi bafite HLA-A * 02 Ibyiza byongeye kugaruka, kuvunika, cyangwa Metastatike HPV16 ifitanye isano na Oropharyngeal, Inkondo y'umura, cyangwa Anal

Iki cyiciro cya Ib / II cyiga ingaruka mbi hamwe nigipimo cyiza cyurukingo rwa HPV16-E711-19 nanomer DPX-E7 no kureba uburyo ikora neza iyo itanzwe hamwe na cyclophosphamide mukuvura abarwayi bafite HLA-A * 02 nziza, papillomavirus yumuntu 16 ( HPV16) ifitanye isano na oropharyngeal, kanseri y'inkondo y'umura, cyangwa anal yagarutse, ntiyitabira kwivuza, cyangwa yakwirakwiriye mu bindi bice by'umubiri. Inkingo zakozwe na virusi yahinduwe na gen irashobora gufasha umubiri kubaka ubudahangarwa bw'umubiri bwo kwica selile. Ibiyobyabwenge bikoreshwa muri chimiotherapie, nka cyclophosphamide, bikora muburyo butandukanye bwo guhagarika imikurire ya selile yibibyimba, haba mukwica selile, kubabuza gutandukana, cyangwa kubabuza gukwirakwira. Gutanga urukingo rwa HPV16-E711-19 nanomer DPX-E7 hamwe na cyclophosphamide birashobora gukora neza mukuvura abarwayi bafite indwara ya HPV16 ifitanye isano na oropharyngeal,

Aho uherereye: Ikigo cya Dana-Farber Kanseri, Boston, Massachusetts

Nivolumab na Ipilimumab mu kuvura abarwayi bafite ibibyimba bidasanzwe

Iki cyiciro cya II cyikigereranyo cyiga nivolumab na ipilimumab mukuvura abarwayi bafite ibibyimba bidasanzwe. Immunotherapy hamwe na antibodiyite za monoclonal, nka nivolumab na ipilimumab, irashobora gufasha sisitemu yumubiri yumubiri gutera kanseri, kandi irashobora kubangamira ubushobozi bwingirabuzimafatizo yibibyimba gukura no gukwirakwira. Uru rubanza rwandikisha abitabiriye amahugurwa akurikira hashingiwe ku miterere: 1. Ibibyimba bya Epiteliyale yo mu cyuho cyo mu mazuru, sinus, nasofarynx: A) Kanseri y'udukoko twitwa kanseri yo mu mazuru, sinus, na nasofarynx na trachea (ukuyemo kanseri yo mu kanwa, izuru [NPC] , na kanseri y'utugingo ngengabuzima twa kanseri yo mu mutwe no mu ijosi [SCCHN]) B) Adenocarcinoma n'ibihinduka byo mu kiziba cy'amazuru, sinus, na nasofarynx (bifunze kugeza kuri 07/27/2018) 2. Ibibyimba bya Epiteliyale ya glande nini y'amacandwe (bifunze kugeza kuri 03 / 20/2018) 3. Amacandwe yo mu bwoko bwa salivary yibibyimba byumutwe nijosi, iminwa, esofagusi, igifu, trachea nibihaha, amabere nahandi hantu (hafunzwe kugirango habeho) 4. Kanseri idatandukanijwe ya gastrointestinal (GI) 5. Adenocarcinoma ifite amara mato mato (ifunze kugeza kubarwa 05/10/2018) 6. Kanseri y'utugingo ngengabuzima twa kanseri ya GI (amara mato mato, igifu, urukiramende, pancreas) (ifunze kugeza ku ya 10/17/2018) 7. Fibromixoma na mucinous adenocarcinoma yo mu rwego rwo hasi (pseudomixoma peritonei) ya umugereka na ovary (bifunze kugeza kuri 03/20/2018) 8. Ibibyimba bidasanzwe byitwa pancreatic kanseri harimo kanseri ya acinar selile, mucinous cystadenocarcinoma cyangwa cystadenocarcinoma serous. Indwara ya pancreatic adenocarcinoma ntabwo yemerewe 9. Intrahepatic cholangiocarcinoma (ifunze kugeza kuri 03/20/2018) 10. Indwara ya cholangiocarcinoma idasanzwe hamwe n'ibibyimba byo mu mara (bifunze kugeza ku ya 03/20/2018) 11. Kanseri ya Sarcomatoide y'ibihaha 12. Bronchoalveolar carcinoma ibihaha. Iyi ndwara ubu nanone yitwa adenocarcinoma mu mwanya, adenocarcinoma yibasiye cyane, lepidic yiganjemo adenocarcinoma, cyangwa adenocarcinoma yibasira 13. Ibibyimba bitari epiteliyale yintanga ngore: A) Ikibyimba cya selile ya ovary B) Mullerian ivanze na adenosarcoma. kumenyekanisha 03/30/2018) 14. Ikibyimba cya Trophoblastique: A) Choriocarcinoma (ifunze kugeza kuri 04/15/2019) 15. Kanseri y'inzibacyuho y'inzibacyuho itari iy'impyiko, pelvis, ureter, cyangwa uruhago (ifunze kugeza kuri 04 / 15/2019) 16. Ikibyimba cy'uturemangingo twa teste na kanseri ya mikorobe idasanzwe: Ibibyimba bya Apocrine / extraramammary Indwara ya Paget 40. Peritoneal mesothelioma 41. Kanseri y'ibanze ya kanseri 42. Kanseri y'inkondo y'umura isukuye 43. Esthenioneuroblastoma 44. Kanseri ya endometrale (ibibyimba bivanze na Mullerian) (ifunze kugeza kuri kanseri) 45. Sobanura neza kanseri y'inkondo y'umura. kanseri y'intanga 47. Indwara ya trophoblastique (GTD) 48. Kanseri ya Gallbladder 49. Kanseri ntoya ya selile yintanga ngore, ubwoko bwa hypercalcemic 50. PD-L1 ibibyimba byongerewe imbaraga 51. Angiosarcoma 52. Kanseri yo mu rwego rwo hejuru ya neuroendocrine (ikibyimba cya pancreatic neuroendocrine [PNET] igomba kwiyandikisha muri Cohort 22; kanseri ya prostate neuroendocrine igomba kwandikwa muri Cohort 53). Kanseri y'ibihaha ntoya ntabwo yemerewe 53. Kuvura-kanseri ntoya ya neuroendocrine kanseri ya prostate (t-SCNC) Kanseri y'inkondo y'umura isukuye 43. Esthenioneuroblastoma 44. Carcinosarcoma ya Endometrale (ibibyimba bivanze na Mullerian ibibyimba) (ifunze kugeza kuri accrual) 45. Sobanura kanseri y'inkondo y'umura kanseri y'inkondo y'umura 46. Kanseri y'intanga ngore 47. Indwara ya trophoblastique (GTD) 48. Kanseri ntoya kanseri y'uturemangingo twa ovary, hypercalcemic ubwoko 50. PD-L1 ibibyimba byongerewe imbaraga 51. Angiosarcoma 52. Kanseri yo mu rwego rwo hejuru ya neuroendocrine kanseri (pancreatic neuroendocrine tumor [PNET] igomba kwandikwa muri Cohort 22; kanseri ya prostate neuroendocrine igomba kwandikwa muri Cohort 53). Kanseri y'ibihaha ntoya ntabwo yemerewe 53. Kuvura-kanseri ntoya ya neuroendocrine kanseri ya prostate (t-SCNC) Kanseri y'inkondo y'umura isukuye 43. Esthenioneuroblastoma 44. Carcinosarcoma ya Endometrale (ibibyimba bivanze na Mullerian ibibyimba) (ifunze kugeza kuri accrual) 45. Sobanura kanseri y'inkondo y'umura kanseri y'inkondo y'umura 46. Kanseri y'intanga ngore 47. Indwara ya trophoblastique (GTD) 48. Kanseri ntoya kanseri y'uturemangingo twa ovary, hypercalcemic ubwoko 50. PD-L1 ibibyimba byongerewe imbaraga 51. Angiosarcoma 52. Kanseri yo mu rwego rwo hejuru ya neuroendocrine kanseri (pancreatic neuroendocrine tumor [PNET] igomba kwandikwa muri Cohort 22; kanseri ya prostate neuroendocrine igomba kwandikwa muri Cohort 53). Kanseri y'ibihaha ntoya ntabwo yemerewe 53. Kuvura-kanseri ntoya ya neuroendocrine kanseri ya prostate (t-SCNC) Kanseri y'intanga ngore 47. Indwara ya trophoblastique (GTD) 48. Kanseri ya Gallbladder 49. Kanseri ntoya ya ovaire, ubwoko bwa hypercalcemic 50. PD-L1 ibibyimba byongerewe imbaraga 51. Angiosarcoma 52. Kanseri yo mu rwego rwo hejuru (kanseri ya pancreatic neuroendocrine [PNET ] igomba kwiyandikisha muri Cohort 22; kanseri ya prostate neuroendocrine igomba kwandikwa muri Cohort 53). Kanseri y'ibihaha ntoya ntabwo yemerewe 53. Kuvura-kanseri ntoya ya neuroendocrine ya prostate (t-SCNC) Kanseri y'intanga ngore 47. Indwara ya trophoblastique (GTD) 48. Kanseri ya Gallbladder 49. Kanseri ntoya ya ovary, ubwoko bwa hypercalcemic 50. PD-L1 ibibyimba byongerewe imbaraga 51. Angiosarcoma 52. Kanseri yo mu rwego rwo hejuru (kanseri ya pancreatic neuroendocrine [PNET ] igomba kwiyandikisha muri Cohort 22; kanseri ya prostate neuroendocrine igomba kwandikwa muri Cohort 53). Kanseri y'ibihaha ntoya ntabwo yemerewe 53. Kuvura-kanseri ntoya ya neuroendocrine ya prostate (t-SCNC) kanseri ya prostate neuroendocrine igomba kwandikwa muri Cohort 53). Kanseri y'ibihaha ntoya ntabwo yemerewe 53. Kuvura-kanseri ntoya ya neuroendocrine ya prostate (t-SCNC) kanseri ya prostate neuroendocrine igomba kwandikwa muri Cohort 53). Kanseri y'ibihaha ntoya ntabwo yemerewe 53. Kuvura-kanseri ntoya ya neuroendocrine kanseri ya prostate (t-SCNC)

Aho uherereye: 878